ArticleFrontiers in medicine2022

Subcutaneous IL-6 Inhibitor Sarilumab vs. Standard Care in Hospitalized Patients With Moderate-To-Severe COVID-19: An Open Label Randomized Clinical Trial.

Rosario García-Vicuña et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.